News

SGS announced that it will commence its first Malaria Volunteer Infection Study (VIS) in Belgium in February 2019 on behalf of Medicines for Malaria Venture (MMV), a product development…
Read More...

Regeneron Pharmaceuticals and Sanofi announced that Praluent (alirocumab) will be made available at a new reduced U.S. list price of $5,850annually, a 60% reduction from the original…
Read More...

The Epilepsy Society and UCB, a global biopharmaceutical company headquartered in Belgium, with a significant UK R&D hub in Slough, UK, have announced an exciting new collaboration…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and…
Read More...

RegeneRx Biopharmaceuticals announced that ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, has executed an agreement with Ora, Inc., located in Andover, Massachusetts,…
Read More...

Eton Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain U.S.…
Read More...

WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200. Per the…
Read More...

3SBio Inc. and Verseau Therapeutics, Inc. announced a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of…
Read More...

Moberg Pharma AB has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe. Under the agreement, Moberg Pharma is eligible to receive up to EUR 50…
Read More...

GlaxoSmithKline plc and Merck KGaA, Darmstadt, Germany announced that they have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa).…
Read More...

Xencor announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics,…
Read More...

Evotec AG and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme,…
Read More...

Fate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural…
Read More...

Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.…
Read More...

Cannabics Pharmaceuticals announced that it has entered into agreement with Wize Pharma, a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and…
Read More...

BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey,…
Read More...

Pathios Therapeutics and Sygnature Discovery sign strategic partnership to discover novel GPR65 modulators for the treatment of autoimmune disease and cancer. Pathios Therapeutics,…
Read More...

Taiho Pharmaceuticaland Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Novelion Therapeutics Inc. announced that its subsidiary, Aegerion Pharmaceuticals has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. for the…
Read More...

Taiho Pharmaceutical and Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...